INFUSION OF VINCRISTINE AND DOXORUBICIN WITH ORAL DEXAMETHASONE AS FIRST-LINE THERAPY FOR MULTIPLE MYELOMA
- 1 October 1989
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 334 (8668), 882-885
- https://doi.org/10.1016/s0140-6736(89)91549-3
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- INCREASE IN CLONOGENIC TUMOUR CELLS IN BONE MARROW OF PATIENTS WITH MULTIPLE MYELOMA TREATED WITH VINCRISTINE, DOXORUBICIN, AND METHYLPREDNISOLONEThe Lancet, 1988
- Results of the mrc myelomatosis trials for patients entered since 1980Hematological Oncology, 1988
- A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patientsBritish Journal of Cancer, 1988
- Multiple myeloma treated with high dose intravenous melphalanBritish Journal of Haematology, 1987
- Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating AgentsNew England Journal of Medicine, 1984
- HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMAThe Lancet, 1983
- Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study.Journal of Clinical Oncology, 1983
- Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assayCancer Chemotherapy and Pharmacology, 1983
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977
- A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survivalCancer, 1975